oral regimen

Cecilia BrownMeeting News | November 22, 2022
Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...
Kerri FitzgeraldChronic Lymphocytic Leukemia | February 1, 2023
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement